Tratamientos avanzados de agua potable para eliminación de materia orgánica disuelta : aplicación del BAC

Los procesos de biofiltración por carbón activo biológico se han utilizado desde hace décadas, primeramente en Europa y después en Norte América, sin embargo no hay parámetros de diseño y operación específicos que se puedan utilizar de guía para la biofiltración. Además, el factor coste a la hora de elegir el carbón activo como medio de filtración impacta en el presupuesto, debido al elevado coste de inversión y de regeneración. A la hora de diseñar y operar filtros de carbón activo los requisitos que comúnmente se buscan son eliminar materia orgánica, olor, y sabor de agua. Dentro de la eliminación de materia orgánica se precisa la eliminación necesaria para evitar subproductos en la desinfección no deseados, y reducir los niveles de carbono orgánico disuelto biodegradable y asimilable a valores que consigan la bioestabilidad del agua producto, a fin de evitar recrecimiento de biofilm en las redes de distribución. El ozono se ha utilizado durante años como un oxidante previo a la biofiltración para reducir el olor, sabor, y color del agua, oxidando la materia orgánica convirtiendo los compuestos no biodegradables y lentamente biodegradables en biodegradables, consiguiendo que puedan ser posteriormente eliminados biológicamente en los filtros de carbón activo. Sin embargo la inestabilidad del ozono en el agua hace que se produzcan ácidos carboxilos, alcoholes y aldehídos, conocidos como subproductos de la desinfección. Con esta tesis se pretende dar respuesta principalmente a los siguientes objetivos: análisis de parámetros requeridos para el diseño de los filtros de carbón activo biológicos, necesidades de ozonización previa a la filtración, y comportamiento de la biofiltración en un sistema compuesto de coagulación sobre un filtro de carbón activo biológico. Los resultados obtenidos muestran que la biofiltración es un proceso que encaja perfectamente con los parámetros de diseño de plantas con filtración convencional. Aunque la capacidad de eliminación de materia orgánica se reduce a medida que el filtro se satura y entra en la fase biológica, la biodegradación en esta fase se mantienen estable y perdura a lo lago de los meses sin preocupaciones por la regeneración del carbón. Los valores de carbono orgánico disuelto biodegradable se mantienen por debajo de los marcados en la literatura existente para agua bioestable, lo que hace innecesaria la dosificación de ozono previa a la biofiltración. La adición de la coagulación con la corrección de pH sobre el carbón activo consigue una mejora en la reducción de la materia orgánica, sin afectar a la biodegradación del carbón activo, cumpliendo también con los requerimientos de turbidez a la salida de filtración. Lo que plantea importantes ventajas para el proceso. Granular activated carbon filters have been used for many years to treat and produce drinking water using the adsorption capacity of carbon, replacing it once the carbon lost its adsorption capacity and became saturated. On the other hand, biological activated carbon filters have been studied for decades, firstly in Europe and subsequently in North America, nevertheless are no generally accepted design and operational parameters documented to be used as design guidance for biofiltration. Perhaps this is because of the cost factor; to choose activated carbon as a filtration media requires a significant investment due to the high capital and regeneration costs. When activated carbon filters are typically required it is for the reduction of an organic load, removal of colour, taste and / or odour. In terms of organic matter reduction, the primary aim is to achieve as much removal as possible to reduce or avoid the introduction of disinfection by products, the required removal in biodegradable dissolved organic carbon and assimilable organic carbon to produce a biologically stable potable water which prohibits the regrowth of biofilm in the distribution systems. The ozone has historically been used as an oxidant to reduce colour, taste and odour by oxidizing the organic matter and increasing the biodegradability of the organic matter, enhancing the effectiveness of organic removal in downstream biological activated carbon filters. Unfortunately, ozone is unstable in water and reacts with organic matter producing carboxylic acids, alcohols, and aldehydes, known as disinfection by products. This thesis has the following objectives: determination of the required parameters for the design of the biological activated filters, the requirement of ozonization as a pre-treatment for the biological activated filters, and a performance assessment of biofiltration when coagulation is applied as a pretreatment for biological activated carbon filters. The results show that the process design parameters of biofiltration are compatible with those of conventional filtration. The organic matter removal reduces its effectiveness as soon as the filter is saturated and the biological stage starts, but the biodegradation continues steadily and lasts for a long period of time without the need of carbon regeneration. The removal of the biodegradable dissolved organic carbon is enough to produce a biostable water according to the values shown on the existing literature; therefore ozone is not required prior to the filtration. Furthermore, the addition of coagulant and pH control before the biological activated carbon filter achieves a additional removal of organic matter, without affecting the biodegradation that occurs in the activated carbon whilst also complying with the required turbidity removal.

Investigación sobre tratamientos de aguas seguros en emergencias

Esta Tesis Doctoral tiene como principal objetivo el obtener una cadena de tratamientos seguros de aguas seriados que nos permita asegurar la calidad de las aguas para consumo humano en caso de emergencias, de tal forma que se minimicen los efectos de acciones hostiles, como sabotajes o actos terroristas, desastres naturales, etc y buscar soluciones adecuadas para garantizar en este caso la salud. Las plantas de tratamientos de aguas existentes comercialmente no aseguran dicha calidad y la documentación sobre el tema presenta vacíos de conocimiento, contradicciones entre resultados de investigaciones o insostenibilidad de conclusiones de las mismas. Estas carencias nos permiten determinar los aspectos a tratar durante la investigación. Por ello, este objetivo se concretó en tres acciones: Investigar sobre rendimientos de plantas convencionales en eliminación de microorganismos y productos tóxicos y peligrosos. Introducir mejoras que garanticen el rendimiento de las plantas convencionales. Investigar sobre la conveniencia de complementar las instalaciones existentes buscando seguridad y garantía sanitaria. Y se desarrollaron tres líneas de investigación: LI 1 “Inorgánicos”: Investigación sobre la eliminación de los metales boro, cobre y molibdeno mediante procesos de intercambio iónico y de coagulaciónfloculación- decantación. LI 2 “Compuestos Orgánicos Volátiles”: Investigación sobre la eliminación de los compuestos orgánicos 1,1 dicloroetano, 1,2 dicloroetano, clorobenceno, 1,3 dicloropropeno y hexacloro 1,3 butadieno mediante procesos de carbón activo granular y de oxidación avanzada. LI 3 “Plantas portátiles”: Investigación sobre plantas existentes portátiles para verificar su rendimiento teórico y proponer mejoras. Estas líneas de investigación se desarrollaron tanto en el nivel teórico como en el empírico, bien sea en laboratorio como en campo. A lo largo del documento se demuestra que las principales fuentes de contaminación, salvo la degradación de yacimientos naturales, proceden de la actividad humana (efluentes industriales y agrícolas, aguas residuales y actividades beligerantes) que provocan un amplio espectro de enfermedades por lo que dificultan tanto la definición de la fuente como la anticipada detección de la enfermedad. Las principales conclusiones que se obtuvieron están relacionadas con el rendimiento de eliminación de los parámetros tras la aplicación de los procesos y plantas de tratamiento de aguas anteriormente reseñadas. Sin embargo, el verdadero elemento designador de originalidad de esta Tesis Doctoral, tal como se ha reseñado arriba, radica en la definición de un sistema seriado de procesos de tratamiento de aguas que asegura la calidad en caso de emergencia. Éste se define en el siguiente orden: pretratamiento, oxidación, coagulación-floculación-decantación, filtración por arena, intercambio iónico, carbón activo granular, microfiltración, radiación UV, ósmosis inversa, radiación UV y cloración final. The main objective of this Thesis is to obtain a chain of stepwise safe water treatments that allow us to ensure the quality of water for human consumption in case of emergencies, so that the effects of hostile actions, such as sabotage or terrorism, natural disasters, etc. and seek appropriate solutions in this case to ensure health. The existing commercial water treatment plants do not ensure quality, and the documentation on the subject presents knowledge gaps or contradictions. These gaps allow us to determine the issues to be discussed during the investigation. Therefore, this objective was manifested in three actions: Researching yields in commercial plants and microorganisms, or toxic and dangerous products removal. Improvements to ensure the performance of conventional plants. Inquire about the advisability of implementing existing facilities for safety and health guarantee. And three lines of research are developed: LI 1 “Inorganic elements”: Research removing metals iron, copper and molybdenum by ion exchange processes and coagulation-flocculation-decantation. LI 2 “Volatile Organic Compounds”: Research removing organic compounds 1,1 dichloroethane, 1,2 dichloroethane, chlorobenzene, 1,3-dichloropropene and 1,3-butadiene hexachloro through processes of granular activated carbon and advanced oxidation. LI 3 “Compact Water Treatment Plants”: Research on existing packaged plants to verify theoretical performance and suggest improvements. These lines of research are developed both theoretically and empirically, both in the laboratory and in the field. Throughout the document, it is evident that the main sources of pollution, other than the degradation of natural deposits, come from human activity (industrial and agricultural effluents, sewage and belligerent activities) which cause a broad spectrum of diseases which hamper both the definition of the source and the early detection of the disease. The main conclusions drawn are related to both the removal efficiency parameters after application of processes and treatment plants outlined above water. However, the real designator of originality of this thesis, such as outlined above, lies in the definition of a serial system water treatment processes assuring quality in case of emergency. This is defined in the following order: pretreatment, oxidation, coagulation-flocculation-sedimentation, sand filtration, ion exchange, granular activated carbon, microfiltration, UV radiation, reverse osmosis, UV radiation and final chlorination.

Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII

Recent studies suggested that modification of the membrane contact site of vitamin K-dependent proteins may enhance the membrane affinity and function of members of this protein family. The properties of a factor VII mutant, factor VII-Q10E32, relative to wild-type factor VII (VII, containing P10K32), have been compared. Membrane affinity of VII-Q10E32 was about 20-fold higher than that of wild-type factor VII. The rate of autoactivation VII-Q10E32 with soluble tissue factor was 100-fold faster than wild-type VII and its rate of activation by factor Xa was 30 times greater than that of wild-type factor VII. When combined with soluble tissue factor and phospholipid, activated factor VII-Q10E32 displayed increased activation of factor X. Its coagulant activity was enhanced in all types of plasma and with all sources of tissue factor tested. This difference in activity (maximum 50-fold) was greatest when coagulation conditions were minimal, such as limiting levels of tissue factor and/or phospholipid. Because of its enhanced activity, factor VII-Q10E32 and its derivatives may provide important reagents for research and may be more effective in treatment of bleeding and/or clotting disorders.

Hypotension and inflammatory cytokine gene expression triggered by factor Xa–nitric oxide signaling

The signaling pathway initiated by factor Xa on vascular endothelial cells was investigated. Factor Xa stimulated a 5- to 10-fold increased release of nitric oxide (NO) in a dose-dependent reaction (0.1–2.5 μg/ml) unaffected by the thrombin inhibitor hirudin but abolished by active site inhibitors, tick anticoagulant peptide, or Glu-Gly-Arg-chloromethyl ketone. In contrast, the homologous clotting protease factor IXa or another endothelial cell ligand, fibrinogen, was ineffective. A factor Xa inter-epidermal growth factor synthetic peptide L83FTRKL88(G) blocking ligand binding to effector cell protease receptor-1 inhibited NO release by factor Xa in a dose-dependent manner, whereas a control scrambled peptide KFTGRLL was ineffective. Catalytically active factor Xa induced hypotension in rats and vasorelaxation in the isolated rat mesentery, which was blocked by the NO synthase inhibitor l-NG-nitroarginine methyl ester (l-NAME) but not by d-NAME. Factor Xa/NO signaling also produced a dose-dependent endothelial cell release of interleukin 6 (range 0.55–3.1 ng/ml) in a reaction inhibited by l-NAME and by the inter-epidermal growth factor peptide Leu83–Leu88 but unaffected by hirudin. Maximal induction of interleukin 6 mRNA required a brief, 30-min stimulation with factor Xa, unaffected by subsequent addition of tissue factor pathway inhibitor. These data suggest that factor Xa-induced NO release modulates endothelial cell-dependent vasorelaxation and cytokine gene expression. This pathway requiring factor Xa binding to effector cell protease receptor-1 and a secondary step of ligand-dependent proteolysis may preserve an anti-thrombotic phenotype of endothelium but also trigger acute phase responses during activation of coagulation in vivo.

Tissue factor gene expression in the adipose tissues of obese mice

Altered expression of proteins of the fibrinolytic and coagulation cascades in obesity may contribute to the cardiovascular risk associated with this condition. We previously reported that plasminogen activator inhibitor 1 (PAI-1) is dramatically up-regulated in the plasma and adipose tissues of genetically obese mice. This change may disturb normal hemostatic balance and create a severe hypofibrinolytic state. Here we show that tissue factor (TF) gene expression also is significantly elevated in the epididymal and subcutaneous fat pads from ob/ob mice compared with their lean counterparts, and that its level of expression in obese mice increases with age and the degree of obesity. Cell fractionation and in situ hybridization analysis of adipose tissues indicate that TF mRNA is increased in adipocytes and in unidentified stromal vascular cells. Transforming growth factor β (TGF-β) is known to be elevated in the adipose tissue of obese mice, and administration of TGF-β increased TF mRNA expression in adipocytes in vivo and in vitro. These observations raise the possibility that TF and TGF-β may contribute to the increased cardiovascular disease that accompanies obesity and related non-insulin-dependent diabetes mellitus, and that the adipocyte plays a key role in this process. The recent demonstration that TF also influences angiogenesis, cell adhesion, and signaling suggests that its exact role in adipose tissue physiology/pathology, may be complex.

Prothrombin deficiency results in embryonic and neonatal lethality in mice

The conversion of prothrombin (FII) to the serine protease, thrombin (FIIa), is a key step in the coagulation cascade because FIIa triggers platelet activation, converts fibrinogen to fibrin, and activates regulatory pathways that both promote and ultimately suppress coagulation. However, several observations suggest that FII may serve a broader physiological role than simply stemming blood loss, including the identification of multiple G protein-coupled, thrombin-activated receptors, and the well-documented mitogenic activity of FIIa in in vitro test systems. To explore in greater detail the physiological roles of FII in vivo, FII-deficient (FII−/−) mice were generated. Inactivation of the FII gene leads to partial embryonic lethality with more than one-half of the FII−/− embryos dying between embryonic days 9.5 and 11.5. Bleeding into the yolk sac cavity and varying degrees of tissue necrosis were observed in many FII−/− embryos within this gestational time frame. However, at least one-quarter of the FII−/− mice survived to term, but ultimately they, too, developed fatal hemorrhagic events and died within a few days of birth. This study directly demonstrates that FII is important in maintaining vascular integrity during development as well as postnatal life.

Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice

Deficiency of blood coagulation factor V or tissue factor causes the death of mouse embryos by 10.5 days of gestation, suggesting that part of the blood coagulation system is necessary for development. This function is proposed to require either generation of the serine protease thrombin and cell signaling through protease-activated receptors or an activity of tissue factor that is distinct from blood clotting. We find that murine deficiency of prothrombin clotting factor 2 (Cf2) was associated with the death of approximately 50% of Cf2−/− embryos by embryonic day 10.5 (E10.5), and surviving embryos had characteristic defects in yolk sac vasculature. Most of the remaining Cf2−/− embryos died by E15.5, but those surviving to E18.5 appeared normal. The rare Cf2−/− neonates died of hemorrhage on the first postnatal day. These studies suggest that a part of the blood coagulation system is adapted to perform a developmental function. Other mouse models show that the absence of platelets or of fibrinogen does not cause fetal wastage. Therefore, the role of thrombin in development may be independent of its effects on blood coagulation and instead may involve signal transduction on cells other than platelets.

Primary structure and tissue distribution of two novel proline-rich γ-carboxyglutamic acid proteins

Two human cDNAs that encode novel vitamin K-dependent proteins have been cloned and sequenced. The predicted amino acid sequences suggest that both are single-pass transmembrane proteins with amino-terminal γ-carboxyglutamic acid-containing domains preceded by the typical propeptide sequences required for posttranslational γ-carboxylation of glutamic acid residues. The polypeptides, with deduced molecular masses of 23 and 17 kDa, are proline-rich within their putative cytoplasmic domains and contain several copies of the sequences PPXY and PXXP, motifs found in a variety of signaling and cytoskeletal proteins. Accordingly, these two proteins have been called proline-rich Gla proteins (PRGP1 and PRGP2). Unlike the γ-carboxyglutamic acid domain-containing proteins of the blood coagulation cascade, the two PRGPs are expressed in a variety of extrahepatic tissues, with PRGP1 and PRGP2 most abundantly expressed in the spinal cord and thyroid, respectively, among those tissues tested. Thus, these observations suggest a novel physiological role for these two new members of the vitamin K-dependent family of proteins.

Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity

Extravascular procoagulant activity often accompanies cell-mediated immune responses and systemic administration of pharmacologic anticoagulants prevents cell-mediated delayed-type hypersensitivity reactions. These observations suggest a direct association between coagulation and cell-mediated immunity. The cytokine interleukin (IL)-4 potently suppresses cell-mediated immune responses, but its mechanism of action remains to be determined. Herein we demonstrate that the physiologic anticoagulant protein S is IL-4-inducible in primary T cells. Although protein S was known to inhibit the classic factor Va-dependent prothrombinase assembled by endothelial cells and platelets, we found that protein S also inhibits the factor Va-independent prothrombinase assembled by lymphoid cells. Thus, protein S-mediated down-regulation of lymphoid cell procoagulant activity may be one mechanism by which IL-4 antagonizes cell-mediated immunity.

Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: Up-regulation of poly(A) polymerase

Tissue factor (TF) is the cellular receptor for an activated form of clotting factor VII (VIIa) and the binding of factor VII(a) to TF initiates the coagulation cascade. Sequence and structural patterns extracted from a global alignment of TF confers homology with interferon receptors of the cytokine receptor super family. Several recent studies suggested that TF could function as a genuine signal transducing receptor. However, it is unknown which biological function(s) of cells are altered upon the ligand, VIIa, binding to TF. In the present study, we examined the effect of VIIa binding to cell surface TF on cellular gene expression in fibroblasts. Differential mRNA display PCR technique was used to identify transcriptional changes in fibroblasts upon VIIa binding to TF. The display showed that VIIa binding to TF either up or down-regulated several mRNA species. The differential expression of one such transcript, VIIa-induced up-regulation, was confirmed by Northern blot analysis. Isolation of a full-length cDNA corresponding to the differentially expressed transcript revealed that VIIa-up-regulated gene was poly(A) polymerase. Northern blot analysis of various carcinomas and normal human tissues revealed an over expression of PAP in cancer tissues. Enhanced expression of PAP upon VIIa binding to tumor cell TF may potentially play an important role in tumor metastasis.

The anticoagulant activation of antithrombin by heparin

Antithrombin, a plasma serpin, is relatively inactive as an inhibitor of the coagulation proteases until it binds to the heparan side chains that line the microvasculature. The binding specifically occurs to a core pentasaccharide present both in the heparans and in their therapeutic derivative heparin. The accompanying conformational change of antithrombin is revealed in a 2.9-Å structure of a dimer of latent and active antithrombins, each in complex with the high-affinity pentasaccharide. Inhibitory activation results from a shift in the main sheet of the molecule from a partially six-stranded to a five-stranded form, with extrusion of the reactive center loop to give a more exposed orientation. There is a tilting and elongation of helix D with the formation of a 2-turn helix P between the C and D helices. Concomitant conformational changes at the heparin binding site explain both the initial tight binding of antithrombin to the heparans and the subsequent release of the antithrombin–protease complex into the circulation. The pentasaccharide binds by hydrogen bonding of its sulfates and carboxylates to Arg-129 and Lys-125 in the D-helix, to Arg-46 and Arg-47 in the A-helix, to Lys-114 and Glu-113 in the P-helix, and to Lys-11 and Arg-13 in a cleft formed by the amino terminus. This clear definition of the binding site will provide a structural basis for developing heparin analogues that are more specific toward their intended target antithrombin and therefore less likely to exhibit side effects.

Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa

Protease-activated receptor 2 (PAR2) is expressed by vascular endothelial cells and other cells in which its function and physiological activator(s) are unknown. Unlike PAR1, PAR3, and PAR4, PAR2 is not activatable by thrombin. Coagulation factors VIIa (FVIIa) and Xa (FXa) are proteases that act upstream of thrombin in the coagulation cascade and require cofactors to interact with their substrates. These proteases elicit cellular responses, but their receptor(s) have not been identified. We asked whether FVIIa and FXa might activate PARs if presented by their cofactors. Co-expression of tissue factor (TF), the cellular cofactor for FVIIa, together with PAR1, PAR2, PAR3, or PAR4 conferred TF-dependent FVIIa activation of PAR2 and, to lesser degree, PAR1. Responses to FXa were also observed but were independent of exogenous cofactor. The TF/FVIIa complex converts the inactive zymogen Factor X (FX) to FXa. Strikingly, when FX was present, low picomolar concentrations of FVIIa caused robust signaling in cells expressing TF and PAR2. Responses in keratinocytes and cytokine-treated endothelial cells suggested that PAR2 may be activated directly by TF/FVIIa and indirectly by TF/FVIIa-generated FXa at naturally occurring expression levels of TF and PAR2. These results suggest that PAR2, although not activatable by thrombin, may nonetheless function as a sensor for coagulation proteases and contribute to endothelial activation in the setting of injury and inflammation. More generally, these findings highlight the potential importance of cofactors in regulating PAR function and specificity.

Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa

Factor VIIa (VIIa), the serine protease that initiates the coagulation pathways, is catalytically activated upon binding to its cell surface receptor and cofactor tissue factor (TF). This study provides a comprehensive analysis of the functional surface of VIIa by alanine scanning mutagenesis of 112 residues. Residue side chains were defined which contribute to TF binding and factor X hydrolysis. Energetically important binding contacts at the interface with TF were identified in the first epidermal growth factor domain of VIIa (Gln-64, Ile-69, Phe-71, Arg-79) and in the protease domain (Arg-277, Met-306, Asp-309). The observed energetic defects are in good agreement with the corresponding residues in TF, suggesting that the VIIa light chain plays a prominent role in high affinity binding of cofactor. Mutation of protease domain interface residues indicated that TF allosterically influences the active site of VIIa. Stabilization of a labile zymogen to enzyme transition could explain the activating effect of TF on VIIa catalytic function. Residues important for factor X hydrolysis were found in three regions of the protease domain: (i) specificity determinants in the catalytic cleft and adjacent loops, (ii) an exosite near the TF binding site, and (iii) a large electronegative exosite which is in a position analogous to the basic exosite I of thrombin. TF regions involved in factor X activation are positioned on the same face of the TF·VIIa complex as the two exosites identified on the protease domain surface, providing evidence for an extended interaction of TF·VIIa with macromolecular substrate.

Unexpected crucial role of residue 225 in serine proteases

Residue 225 in serine proteases of the chymotrypsin family is Pro or Tyr in more than 95% of nearly 300 available sequences. Proteases with Y225 (like some blood coagulation and complement factors) are almost exclusively found in vertebrates, whereas proteases with P225 (like degradative enzymes) are present from bacteria to human. Saturation mutagenesis of Y225 in thrombin shows that residue 225 affects ligand recognition up to 60,000-fold. With the exception of Tyr and Phe, all residues are associated with comparable or greatly reduced catalytic activity relative to Pro. The crystal structures of three mutants that differ widely in catalytic activity (Y225F, Y225P, and Y225I) show that although residue 225 makes no contact with substrate, it drastically influences the shape of the water channel around the primary specificity site. The activity profiles obtained for thrombin also suggest that the conversion of Pro to Tyr or Phe documented in the vertebrates occurred through Ser and was driven by a significant gain (up to 50-fold) in catalytic activity. In fact, Ser and Phe are documented in 4% of serine proteases, which together with Pro and Tyr account for almost the entire distribution of residues at position 225. The unexpected crucial role of residue 225 in serine proteases explains the evolutionary selection of residues at this position and shows that the structural determinants of protease activity and specificity are more complex than currently believed. These findings have broad implications in the rational design of enzymes with enhanced catalytic properties.

The crayfish plasma clotting protein: A vitellogenin-related protein responsible for clot formation in crustacean blood

Coagulation in crayfish blood is based on the transglutaminase-mediated crosslinking of a specific plasma clotting protein. Here we report the cloning of the subunit of this clotting protein from a crayfish hepatopancreas cDNA library. The ORF encodes a protein of 1,721 amino acids, including a signal peptide of 15 amino acids. Sequence analysis reveals that the clotting protein is homologous to vitellogenins, which are proteins found in vitellogenic females of egg-laying animals. The clotting protein and vitellogenins are all lipoproteins and share a limited sequence similarity to certain other lipoproteins (e.g., mammalian apolipoprotein B and microsomal triglyceride transfer protein) and contain a stretch with similarity to the D domain of mammalian von Willebrand factor. The crayfish clotting protein is present in both sexes, unlike the female-specific vitellogenins. Electron microscopy was used to visualize individual clotting protein molecules and to study the transglutaminase-mediated clotting reaction. In the presence of an endogenous transglutaminase, the purified clotting protein molecules rapidly assemble into long, flexible chains that occasionally branch.